Preclinical evaluation of YC-1, a HIF inhibitor, for the prevention of tumor spreading

Cancer Letters

Volumn 255, Issue 1, 2007, Pages 107-116

  Shin, Dong Hoon ^a   Kim, Jin Ho ^a   Jung, Yu Jung ^a   Kim, Kyung Eun ^a   Jeong, Jae Min ^a   Chun, Yang Sook ^a   Park, Jong Wan ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

HIF 1; Metastasis; Tumor invasion; YC 1

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; ANTINEOPLASTIC AGENT; BETA TUBULIN; GUANYLATE CYCLASE ACTIVATOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER INVASION; CELL MIGRATION; CONTROLLED STUDY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOBLOTTING; LIVER METASTASIS; LUNG METASTASIS; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL MOVEMENT; COLLAGEN; DRUG COMBINATIONS; DRUG SCREENING ASSAYS, ANTITUMOR; GREEN FLUORESCENT PROTEINS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INDAZOLES; LAMININ; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PROTEOGLYCANS;

MUS; MUS MUSCULUS;

EID: 34547660100     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2007.03.026     Document Type: Article

References (39)

1. Hockel M., and Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J. Natl. Cancer Inst. 93 (2001) 266-276
2. Harris A.L. Hypoxia-a key regulatory factor in tumour growth. Nature Rev. Cancer 2 (2002) 38-47
3. Chun Y.S., Kim M.S., and Park J.W. Oxygen-dependent and -independent regulation of HIF-1alpha. J. Korean Med. Sci. 17 (2002) 581-588
4. Wang G.L., and Semenza G.L. Purification and characterization of hypoxia-inducible factor 1. J. Biol. Chem. 270 (1995) 1230-1237
5. 2 sensing. Science 292 (2001) 464-468
6. Jaakkola P., Mole D.R., Tian Y.M., Wilson M.I., Gielbert J., Gaskell S.J., Kriegsheim Av., Hebestreit H.F., Mukherji M., Schofield C.J., Maxwell P.H., Pugh C.W., and Ratcliffe P.J. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292 (2001) 468-472
7. Maxwell P.H., Wiesener M.S., Chang G.W., Clifford S.C., Vaux E.C., Cockman M.E., Wykoff C.C., Pugh C.W., Maher E.R., and Ratcliffe P.J. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399 (1999) 271-275
8. Zhong H., De Marzo A.M., Laughner E., Lim M., Hilton D.A., Zagzag D., Buechler P., Isaacs W.B., Semenza G.L., and Simons J.W. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 59 (1999) 5830-5835
9. Birner P., Schindl M., Obermair A., Plank C., Breitenecker G., and Oberhuber G. Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res. 60 (2000) 4693-4696
10. Zagzag D., Zhong H., Scalzitti J.M., Laughner E., Simons J.W., and Semenza G.L. Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. Cancer 88 (2000) 2606-2618
11. Yeo E.J., Chun Y.S., and Park J.W. New anticancer strategies targeting HIF-1. Biochem. Pharmacol. 68 (2004) 1061-1069
12. Friebe A., and Koesling D. Mechanism of YC-1-induced activation of soluble guanylyl cyclase. Mol. Pharmacol. 53 (1998) 123-127
13. Chun Y.S., Yeo E.J., and Park J.W. Versatile pharmacological actions of YC-1: anti-platelet to anticancer. Cancer Lett. 207 (2004) 1-7
14. Chun Y.S., Yeo E.J., Choi E., Teng C.M., Bae J.M., Kim M.S., and Park J.W. Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells. Biochem. Pharmacol. 61 (2001) 947-954
15. Kim H.L., Yeo E.J., Chun Y.S., and Park J.W. A domain responsible for HIF-1alpha degradation by YC-1, a novel anticancer agent. Int. J. Oncol. 29 (2006) 255-260
16. Yeo E.J., Chun Y.S., Cho Y.S., Kim J., Lee J.C., Kim M.S., and Park J.W. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J. Natl. Cancer Inst. 95 (2003) 516-525
17. Garber K. New drugs target hypoxia response in tumors. J. Natl. Cancer Inst. 97 (2005) 1112-1114
18. Subarsky P., and Hill R.P. The hypoxic tumour microenvironment and metastatic progression. Clin. Exp. Metastasis 20 (2003) 237-250
19. Le Q.T., Denko N.C., and Giaccia A.J. Hypoxic gene expression and metastasis. Cancer Metastasis Rev. 23 (2004) 293-310
20. Chun Y.S., Choi E., Yeo E.J., Lee J.H., Kim M.S., and Park J.W. A new HIF-1 alpha variant induced by zinc ion suppresses HIF-1-mediated hypoxic responses. J. Cell Sci. 114 (2001) 4051-4061
21. Coradini D., Zorzet S., Rossin R., Scarlata I., Pellizzaro C., Turrin C., Bello M., Cantoni S., Speranza A., Sava G., Mazzi U., and Perbellini A. Inhibition of hepatocellular carcinomas in vitro and hepatic metastases in vivo in mice by the histone deacetylase inhibitor HA-But. Clin. Cancer Res. 10 (2004) 4822-4830
22. Nogawa M., Yuasa T., Kimura S., Kuroda J., Sato K., Segawa H., Yokota A., and Maekawa T. Monitoring luciferase-labeled cancer cell growth and metastasis in different in vivo models. Cancer Lett. 217 (2005) 243-253
23. Moeller B.J., Cao Y., Li C.Y., and Dewhirst M.W. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 5 (2004) 429-441
24. Maxwell P.H., Dachs G.U., Gleadle J.M., Nicholls L.G., Harris A.L., Stratford I.J., Hankinson O., Pugh C.W., and Ratcliffe P.J. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc. Natl. Acad. Sci. USA 94 (1997) 8104-8109
25. Ryan H.E., Poloni M., McNulty W., Elson D., Gassmann M., Arbeit J.M., and Johnson R.S. Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth. Cancer Res. 60 (2000) 4010-4015
26. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3 (2003) 721-732
27. Giaccia A., Siim B.G., and Johnson R.S. HIF-1 as a target for drug development. Nat. Rev. Drug. Discov. 2 (2003) 803-811
28. Carmeliet P., Dor Y., Herbert J.M., Fukumura D., Brusselmans K., Dewerchin M., Neeman M., Bono F., Abramovitch R., Maxwell P., Koch C.J., Ratcliffe P., Moons L., Jain R.K., Collen D., and Keshert E. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394 (1998) 485-490
29. Kyzas P.A., Stefanou D., Batistatou A., and Agnantis N.J. Hypoxia-induced tumor angiogenic pathway in head and neck cancer: an in vivo study. Cancer Lett. 225 (2005) 297-304
30. Beasley N.J., Leek R., Alam M., Turley H., Cox G.J., Gatter K., Millard P., Fuggle S., and Harris A.L. Hypoxia-inducible factors HIF-1alpha and HIF-2alpha in head and neck cancer: relationship to tumor biology and treatment outcome in surgically resected patients. Cancer Res. 62 (2002) 2493-2497
31. Erler J.T., Bennewith K.L., Nicolau M., Dornhofer N., Kong C., Le Q.T., Chi J.T., Jeffrey S.S., and Giaccia A.J. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 440 (2006) 1222-1226
32. H.H. Chen, W.C. Su, P.W. Lin, H.R. Guo, W.Y. Lee, Hypoxia-inducible factor-1alpha correlates with MET and metastasis in node-negative breast cancer, Breast Cancer Res. Treat. (in press).
33. Spangenberg C., Lausch E.U., Trost T.M., Prawitt D., May A., Keppler R., Fees S.A., Reutzel D., Bell C., Schmitt S., Schiffer I.B., Weber A., Brenner W., Hermes M., Sahin U., Tureci O., Koelbl H., Hengstler J.G., and Zabel B.U. ERBB2-mediated transcriptional up-regulation of the alpha5beta1 integrin fibronectin receptor promotes tumor cell survival under adverse conditions. Cancer Res. 66 (2006) 3715-3725
34. Pan J., Mestas J., Burdick M.D., Phillips R.J., Thomas G.V., Reckamp K., Belperio J.A., and Strieter R.M. Stromal derived factor-1 (SDF-1/CXCL12) and CXCR4 in renal cell carcinoma metastasis. Mol. Cancer 5 (2006) 56
35. Wilson J.L., Burchell J., and Grimshaw M.J. Endothelins induce CCR7 expression by breast tumor cells via endothelin receptor A and hypoxia-inducible factor-1. Cancer Res. 66 (2006) 11802-11807
36. Funasaka T., Yanagawa T., Hogan V., and Raz A. Regulation of phosphoglucose isomerase/autocrine motility factor expression by hypoxia. FASEB J. 19 (2005) 1422-1430
37. Semenza G.L. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol. Med. 8 (2002) S62-S67
38. Yeo E.J., Ryu J.H., Chun Y.S., Cho Y.S., Jang I.J., Cho H., Kim J., Kim M.S., and Park J.W. YC-1 induces S cell cycle arrest and apoptosis by activating checkpoint kinases. Cancer Res. 66 (2006) 6345-6352
39. Li Z., Jiao X., Wang C., Ju X., Lu Y., Yuan L., Lisanti M.P., Katiyar S., and Pestell R.G. Cyclin D1 induction of cellular migration requires p27(KIP1). Cancer Res. 66 (2006) 9986-9994